Gonadotropin Releasing Hormone Agonists May Minimize Cyclophosphamide Associated Gonadotoxicity in SLE and Autoimmune Diseases

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 3, 2011, Pages 346-352

  Blumenfeld, Zeev ^a   Mischari, Or ^a   Schultz, Naomi ^a   Boulman, Nina ^b   Balbir Gurman, Alexandra ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Connective tissue disease; GnRH a; Gonadotoxicity; Premature ovarian failure; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ESTROGEN; FOLLITROPIN; GONADORELIN AGONIST; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LUTEINIZING HORMONE; METHOTREXATE; PROGESTERONE; TRIPTORELIN;

ADOLESCENT; ADULT; ARAB; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; CLINICAL ARTICLE; CONCEPTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; ECHOGRAPHY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HORMONE DETERMINATION; HUMAN; JEW; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL RECORD REVIEW; MENSTRUATION; MIXED CONNECTIVE TISSUE DISEASE; OVARY FUNCTION; POLYARTERITIS NODOSA; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULITIS;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; CYCLOPHOSPHAMIDE; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRIMARY OVARIAN INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 84860389172     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.05.008     Document Type: Article

References (37)

1. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999, 42:1785-1796. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines.
2. Madhok R., Wu O. Systemic lupus erythematosus. Am Pham Physician 2007, 76:1351-1353.
3. Bellver J., Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril 2009, 92:1803-1810.
4. Mackillop L.H., Germain S.J., Nelson-Piercy C. Systemic lupus erythematosus. BMJ 2007, 335:933-936.
5. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
6. Blumenfeld Z., Shapiro D., Shteinberg M., Avivi I., Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000, 9:401-405.
7. Somers E.C., Marder W., Christman G.M., Ognenovski V., McCune W.J. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005, 52:2761-2767.
8. Manger K., Wildt L., Kalden J.R., Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev 2006, 5:269-272.
9. Liang L.Q., Qiu Q., Yang X.Y., Xu H.S., Ye Y.J., Zhan Z.P., et al. Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide [in Chinese]. Zhonghua Yi Xue Za Zhi 2008, 88:1009-1011.
10. Mersereau J., Dooley M.A. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum Dis Clin North Am 2010, 36:99-108.
11. Grootscholten C., Ligtenberg G., Hagen E.C., van den Wall Bake A.W., de Glas-Vos J.W., Bijl M., et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006, 70:732-742.
12. Grootscholten C., Bajema I.M., Florquin S., Steenbergen E.J., Peutz-Kootstra C.J., Goldschmeding R., et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007, 56:924-937.
13. Sanchez O., Sitbon O., Jaïs X., Simonneau G., Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006, 130:182-189.
14. Hoyles R.K., Ellis R.W., Wellsbury J., Lees B., Newlands P., Goh N.S., et al. A multicenter, prospective, randomized, double blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54:3962-3970.
15. Guillevin L., Cordier J.F., Lhote F., Cohen P., Jarrousse B., Royer I., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997, 40:2187-2198.
16. Jayne D. Review article: Progress of treatment in ANCA-associated vasculitis. Nephrology 2009, 14:42-48.
17. de Groot K., Adu D., Savage C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review. Nephrol Dial Transplant 2001, 16:2018-2027.
18. Sinha R., Dionne J.M. Should gonadotropin releasing hormone analogue be administered to prevent premature ovarian failure in young women with systemic lupus erythematosus on cyclophosphamide therapy?. Arch Dis Child 2008, 93:444-445.
19. Blumenfeld Z. Gynaecologic concerns for young women exposed to gonadotoxic chemotherapy. Curr Opin Obstet Gynecol 2003, 15:359-370.
20. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997, 40:1725.
21. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
22. Alarcon-Segovia D., Cardiel M.H. Comparison between 3 diagnostic criteria for mixed connective tissue disease: study of 593 patients. J Rheumatol 1989, 16:328-334.
23. Watts R., Lane S., Hanslik T., Hauser T., Hellmich B., Koldingsnes W., et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007, 66(2):222-227.
24. McCune W.J., Golbus J., Zeldes W., Bohlke P., Dunne R., Fox D. Clinical and immunologic effects of monthly intravenous cyclophosphamide in severe systemic lupus. N Engl J Med 1988, 318:1423-1431.
25. Trevisani V.F.M., Castro A.A., Ferreira Neves Neto J.J.F.N.N., Atallah Á.N. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database of Systematic Reviews 2006, (2). CD002265.
26. Yazici Y. Systemic vasculitis treatment and monitoring update, 2008. Bull NYU Hosp Jt Dis 2008, 66:228-230.
27. Blumenfeld Z., von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008, 14:543-552. [review].
28. Badawy A., Elnashar A., El-Ashry M., Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009, 91:694-697.
29. Sverrisdottir A., Nystedt M., Johansson H., Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009, 117:561-567.
30. Del Mastro L., Boni L., Michelotti A., Gamucci T., Olmeo N., Giordano M., et al. Role of luteinizing hormone-releasing hormone analog (LH-RHa) triptorelin in preserving ovarian function during chemotherapy for early breast cancer patients: results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol 2010, 28(suppl):15s. [abstract 528].
31. Clowse M.E., Behera M.A., Anders C.K., Copland S., Coffman C.J., Leppert P.C., et al. Ovarian preservation by GnRH agonists during chemotherapy: A meta-analysis. J Womens' Health (Larchmt) 2009, 18:311-339.
32. Ben-Aharon I., Gafter-Gvili A., Leibovici L., Stemmer S.M. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010, 122:803-811.
33. Kim S.S., Lee J.R., Jee B.C., Suh C.S., Kim S.H., Ting A., et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol 2010, 53:740-752.
34. Bedaiwy M.A., Abou-Setta A.M., Desai N., Hurd W., Starks D., El-Nashar S.A., et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011, 95:906-914.
35. Beck-Fruchter R., Weiss A., Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: A review of the clinical data. Hum Reprod Update 2008, 14:553-561.
36. Moore H.C. Ovarian failure after chemotherapy for breast cancer and the role of gonadotropin-releasing hormone analogs in protection of ovarian function 2008, 39-42. American Society of Clinical Oncology Educational Book, ASCO, Alexandria (VA).
37. Meirow D., Rabinovici J., Katz D., Or R., Shufaro Y., Ben-Yehuda D. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006, 107:1634-1641.